Workflow
Tandem Diabetes Care (TNDM) Reports Q3 Earnings: What Key Metrics Have to Say
Tandem Diabetes CareTandem Diabetes Care(US:TNDM) ZACKSยท2024-11-07 00:36

Core Insights - Tandem Diabetes Care, Inc. reported a revenue of $243.97 million for the quarter ended September 2024, reflecting a year-over-year increase of 31.4% [1] - The company's EPS was -$0.36, an improvement from -$0.38 in the same quarter last year [1] - The reported revenue exceeded the Zacks Consensus Estimate of $223.33 million by 9.24%, and the EPS also surpassed the consensus estimate of -$0.43 by 16.28% [1] Performance Metrics - Total worldwide pump shipments reached 32,000, exceeding the average estimate of 29,722 [3] - Pump shipments outside the United States were 11,000, compared to the estimated 8,738 [3] - In the United States, pump shipments totaled 21,000, slightly above the average estimate of 20,985 [3] - U.S. pump sales amounted to $86.72 million, surpassing the average estimate of $84.60 million, marking a 30.7% increase year-over-year [3] - Sales of supplies and other in the U.S. were $83.89 million, exceeding the estimate of $78.68 million, representing a 16.4% year-over-year increase [3] - Geographic sales outside the U.S. reached $72.32 million, compared to the average estimate of $59.84 million, reflecting a 30.5% year-over-year increase [3] - U.S. geographic sales totaled $171.65 million, exceeding the estimate of $163.28 million, with a year-over-year increase of 31.8% [3] - Sales of supplies and other outside the U.S. were $44.24 million, surpassing the estimate of $37.44 million, indicating a 31.2% year-over-year increase [3] - Pump sales outside the U.S. reached $28.08 million, exceeding the estimate of $22.34 million, with a year-over-year increase of 29.6% [3] - Revenue from supplies and other was $128.13 million, compared to the average estimate of $115.91 million [3] - Pump revenue was $114.80 million, exceeding the average estimate of $107.07 million [3] Stock Performance - Tandem Diabetes Care's shares have declined by 17% over the past month, while the Zacks S&P 500 composite has increased by 0.7% [4] - The stock currently holds a Zacks Rank 2 (Buy), suggesting potential outperformance against the broader market in the near term [4]